PE20161344A1 - Determinantes de respuesta del cancer a la inmunoterapia - Google Patents
Determinantes de respuesta del cancer a la inmunoterapiaInfo
- Publication number
- PE20161344A1 PE20161344A1 PE2016000989A PE2016000989A PE20161344A1 PE 20161344 A1 PE20161344 A1 PE 20161344A1 PE 2016000989 A PE2016000989 A PE 2016000989A PE 2016000989 A PE2016000989 A PE 2016000989A PE 20161344 A1 PE20161344 A1 PE 20161344A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen
- composition
- determinants
- immunotherapy
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 206010069754 Acquired gene mutation Diseases 0.000 abstract 1
- 102100026882 Alpha-synuclein Human genes 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 108091035707 Consensus sequence Proteins 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 239000012678 infectious agent Substances 0.000 abstract 1
- 230000037439 somatic mutation Effects 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923183P | 2014-01-02 | 2014-01-02 | |
| US201462066034P | 2014-10-20 | 2014-10-20 | |
| US201462072893P | 2014-10-30 | 2014-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161344A1 true PE20161344A1 (es) | 2016-12-23 |
Family
ID=53494217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000989A PE20161344A1 (es) | 2014-01-02 | 2014-12-23 | Determinantes de respuesta del cancer a la inmunoterapia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160326597A1 (enExample) |
| EP (1) | EP3090066A4 (enExample) |
| JP (1) | JP2017504324A (enExample) |
| KR (1) | KR20160102314A (enExample) |
| CN (1) | CN106164289A (enExample) |
| AU (1) | AU2014374020A1 (enExample) |
| BR (1) | BR112016015399A2 (enExample) |
| CA (1) | CA2935214A1 (enExample) |
| CL (1) | CL2016001708A1 (enExample) |
| MX (1) | MX2016008771A (enExample) |
| PE (1) | PE20161344A1 (enExample) |
| PH (1) | PH12016501329A1 (enExample) |
| RU (1) | RU2707530C2 (enExample) |
| SG (2) | SG11201605432RA (enExample) |
| WO (1) | WO2015103037A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| CA2966660A1 (en) | 2014-11-13 | 2016-05-19 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| IL293135A (en) | 2015-05-13 | 2022-07-01 | Agenus Inc | Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| US11623001B2 (en) * | 2015-10-12 | 2023-04-11 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| JP2018532736A (ja) * | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
| MX387275B (es) * | 2015-10-12 | 2025-03-18 | Nantomics Llc | Neoepítopos virales y sus usos |
| JP6938489B2 (ja) * | 2015-10-23 | 2021-09-22 | ノバルティス・エイジーＮｏｖａｒｔｉｓ ＡＧ | 視野に存在する選択された細胞のバイオマーカー陽性率の値を導き出す方法 |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| EP3400005A1 (en) * | 2016-01-08 | 2018-11-14 | Vaccibody AS | Neoepitope rna cancer vaccine |
| EP3417289B1 (en) | 2016-02-19 | 2020-12-23 | Nant Holdings IP, LLC | Methods of immunogenic modulation |
| CN109196121B (zh) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | 用于癌症的治疗和诊断方法 |
| JP2019509282A (ja) | 2016-02-29 | 2019-04-04 | ファウンデーション・メディシン・インコーポレイテッド | 癌の治療方法 |
| WO2017159686A1 (ja) * | 2016-03-15 | 2017-09-21 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 |
| RU2769314C1 (ru) * | 2016-03-16 | 2022-03-30 | Амаль Терапьютикс Са | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине |
| WO2017214575A1 (en) * | 2016-06-10 | 2017-12-14 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| US20190247435A1 (en) * | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| HUE067838T2 (hu) | 2016-09-21 | 2024-11-28 | Amal Therapeutics Sa | Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére |
| US11332530B2 (en) | 2016-09-23 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| CA3038712A1 (en) * | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| CN110214275B (zh) | 2016-12-01 | 2022-12-06 | 南托米克斯有限责任公司 | 肿瘤抗原性加工和呈递 |
| WO2018112449A2 (en) | 2016-12-16 | 2018-06-21 | Nant Holdings Ip, Llc | Live cell imaging systems and methods to validate triggering of immune response |
| WO2018132753A1 (en) * | 2017-01-13 | 2018-07-19 | Nantbio, Inc. | Validation of neoepitope-based treatment |
| US12331359B2 (en) | 2017-01-18 | 2025-06-17 | Michael Laessig | Neoantigens and uses thereof for treating cancer |
| WO2018146128A1 (en) * | 2017-02-07 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy |
| JP2020511137A (ja) * | 2017-03-17 | 2020-04-16 | ナントミクス，エルエルシー | ｃｆＲＮＡに関する液体生検 |
| KR20250036268A (ko) * | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP3933408A1 (en) | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| US20180357361A1 (en) * | 2017-06-13 | 2018-12-13 | Feliks Frenkel | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
| GB201710815D0 (en) * | 2017-07-05 | 2017-08-16 | Francis Crick Inst Ltd | Method |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| RU2020113600A (ru) | 2017-09-20 | 2021-10-20 | Ридженерон Фармасьютикалз, Инк. | Способы иммунотерапии пациентов, опухоли которых характеризуются высокой нагрузкой пассажирскими генными мутациями |
| CN111432837A (zh) * | 2017-09-25 | 2020-07-17 | 纪念斯隆凯特琳癌症中心 | 肿瘤突变负荷和检查点免疫疗法 |
| EP3688165A4 (en) | 2017-09-25 | 2021-09-29 | Nant Holdings IP, LLC | VALIDATION OF THE PRESENTATION OF NEOEPITOPES |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| EP3704268B1 (en) | 2017-11-03 | 2025-01-22 | Guardant Health, Inc. | Normalizing tumor mutation burden |
| CN111566484A (zh) * | 2017-11-09 | 2020-08-21 | 宾夕法尼亚大学董事会 | 细胞外囊泡蛋白及其在癌症诊断、预测对疗法的反应和治疗中的用途 |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| WO2019109086A1 (en) * | 2017-12-01 | 2019-06-06 | Illumina, Inc. | Methods and systems for determining somatic mutation clonality |
| CN108009400B (zh) * | 2018-01-11 | 2018-07-06 | 至本医疗科技（上海）有限公司 | 全基因组肿瘤突变负荷预测方法、设备以及存储介质 |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| CN120193081A (zh) | 2018-07-23 | 2025-06-24 | 夸登特健康公司 | 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统 |
| AU2019328344B2 (en) | 2018-08-31 | 2025-06-12 | Guardant Health, Inc. | Microsatellite instability detection in cell-free DNA |
| CN109371005B (zh) * | 2018-11-12 | 2022-09-30 | 上海市东方医院（同济大学附属东方医院） | 一种hla-0201限制性padi4表位多肽及其应用 |
| WO2020121226A1 (en) * | 2018-12-12 | 2020-06-18 | Medimmune, Llc | Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer |
| SG11202106708VA (en) * | 2018-12-21 | 2021-07-29 | Agency Science Tech & Res | Method of predicting for benefit from immune checkpoint inhibition therapy |
| CA3104293A1 (en) | 2019-04-05 | 2020-10-08 | Illumina, Inc. | Quantitative score of hla diversity |
| US20200371103A1 (en) * | 2019-05-24 | 2020-11-26 | Iuve, Inc. | Precision Medicine Method for Cancer Immunotherapy |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| NL2024107B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Compositions for Patient Specific Immunotherapy |
| CN111088349B (zh) * | 2020-02-14 | 2023-04-28 | 深圳市宝安区妇幼保健院 | Kir3dl1基因分型引物组及其应用 |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4000595A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| EP4000596A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| US20240192195A1 (en) * | 2021-04-10 | 2024-06-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A multiomic approach to modeling of gene regulatory networks in multiple myeloma |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024216165A1 (en) | 2023-04-12 | 2024-10-17 | Icahn School Of Medicine At Mount Sinai | Computational methods for selecting personalized neoantigen vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
| US9222938B2 (en) * | 2001-12-04 | 2015-12-29 | Michael Tainsky | Neoepitope detection of disease using protein arrays |
| CA2585776A1 (en) * | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| US20100099090A1 (en) * | 2007-03-05 | 2010-04-22 | Bristol-Mayers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
| KR102315754B1 (ko) * | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
-
2014
- 2014-12-23 KR KR1020167021093A patent/KR20160102314A/ko not_active Withdrawn
- 2014-12-23 MX MX2016008771A patent/MX2016008771A/es unknown
- 2014-12-23 PE PE2016000989A patent/PE20161344A1/es unknown
- 2014-12-23 US US15/109,464 patent/US20160326597A1/en not_active Abandoned
- 2014-12-23 RU RU2016131207A patent/RU2707530C2/ru not_active IP Right Cessation
- 2014-12-23 CN CN201480075287.2A patent/CN106164289A/zh active Pending
- 2014-12-23 SG SG11201605432RA patent/SG11201605432RA/en unknown
- 2014-12-23 EP EP14876694.2A patent/EP3090066A4/en not_active Withdrawn
- 2014-12-23 AU AU2014374020A patent/AU2014374020A1/en not_active Abandoned
- 2014-12-23 BR BR112016015399A patent/BR112016015399A2/pt not_active IP Right Cessation
- 2014-12-23 CA CA2935214A patent/CA2935214A1/en not_active Abandoned
- 2014-12-23 JP JP2016544613A patent/JP2017504324A/ja active Pending
- 2014-12-23 SG SG10201805674YA patent/SG10201805674YA/en unknown
- 2014-12-23 WO PCT/US2014/072125 patent/WO2015103037A2/en not_active Ceased
-
2016
- 2016-07-01 CL CL2016001708A patent/CL2016001708A1/es unknown
- 2016-07-04 PH PH12016501329A patent/PH12016501329A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160326597A1 (en) | 2016-11-10 |
| AU2014374020A1 (en) | 2016-08-18 |
| CN106164289A (zh) | 2016-11-23 |
| RU2707530C2 (ru) | 2019-11-27 |
| WO2015103037A3 (en) | 2015-11-05 |
| CA2935214A1 (en) | 2015-07-09 |
| RU2016131207A (ru) | 2018-02-07 |
| JP2017504324A (ja) | 2017-02-09 |
| MX2016008771A (es) | 2016-12-20 |
| SG10201805674YA (en) | 2018-08-30 |
| RU2016131207A3 (enExample) | 2018-06-22 |
| BR112016015399A2 (pt) | 2017-10-24 |
| PH12016501329A1 (en) | 2016-10-03 |
| WO2015103037A2 (en) | 2015-07-09 |
| EP3090066A4 (en) | 2017-08-30 |
| CL2016001708A1 (es) | 2017-03-17 |
| SG11201605432RA (en) | 2016-07-28 |
| KR20160102314A (ko) | 2016-08-29 |
| EP3090066A2 (en) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161344A1 (es) | Determinantes de respuesta del cancer a la inmunoterapia | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
| SA519401072B1 (ar) | Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها | |
| PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| PE20170289A1 (es) | Anticuerpos anti tigit | |
| CO2017007619A2 (es) | Anticuerpos humanos contra glicoproteína del virus ébola | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| MX2015013104A (es) | Composiciones y métodos para la inmunoterapia. | |
| PE20161392A1 (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| MX2015017487A (es) | Anticuerpos cd3 humanizados o quimericos. |